Dr Lal PathLabs

August 1, 2020

National Stock Exchange of India
Limited Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex Bandra (E)
Mumbai – 400 051.

Bombay Stock Exchange Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai- 400001

Sub: Newspaper Publication(s)

Ref: Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations")

Dear Sir/Madam,

Please find attached extract of Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2020, published in Financial Express and Jansatta on August 1, 2020.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Dr. Lal PathLabs Limited

Rajat Kalra
Company Secretary and Legal Head

Encl: As above

Dr Lal PathLabs

Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388
Regd. Office: Block E, Sector-18, Rohini, New Delhi- 110085
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram-122 001, Haryana
Phone: +91 124 3016500; **Fax:** +91 124 4234468; **Website:** www.lalpathlabs.com; **Email:** cs@lalpathlabs.com

Extract of Consolidated Financial Results for the quarter ended 30 June, 2020

(Rs. in million except as stated)

S. No.	Particulars	3 months ended 30 June, 2020	Year ended 31 March, 2020	Corresponding 3 months ended 30 June, 2019
		(Unaudited)	(Audited)	(Unaudited)
1	Total Income from Operations	2,774	13,854	3,496
2	Net Profit for the period before Tax and Exceptional items#	381	3,105	894
3	Net Profit for the period before Tax and after Exceptional items#	381	3,105	894
4	Net Profit for the period after Tax and after Exceptional items#	284	2,276	591
5	Total Comprehensive Income for the period after tax#	275	2,265	595
6	Paid up Equity Share Capital (face value of Rs. 10/- per share)	833	833	833
7	Earnings Per Share (of Rs. 10/- each) (not annualised)			
	(a) Basic (In Rs.)	3.45	27.42	7.14
	(b) Diluted (In Rs.)	3.44	27.37	7.13

#Before non-controlling Interest

Notes:

i. Key numbers of the Standalone Results are as under:

(Rs. in million except as stated)

S. No.	Particulars	3 months ended 30 June, 2020	Year ended 31 March, 2020	Corresponding 3 months ended 30 June, 2019
		(Unaudited)	(Audited)	(Unaudited)
1	Total Income from Operations	2,661	13,312	3,386
2	Profit for the period before Tax	385	3,027	867
3	Profit for the period after Tax	288	2,232	573
4	Total comprehensive income	279	2,221	577

ii. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 31 July, 2020.

iii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', prescribed under Section 133 of the Companies Act, 2013.

iv. The above is an extract of the detailed format of Quarterly financial results as per Ind AS filed with the Stock Exchange under Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015. The full Financial Results of the Quarter ended is available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and the Company's website (www.lalpathlabs.com).

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited

Place: Gurugram
Date: 31 July, 2020

Dr. Om Prakash Manchanda
Managing Director

Dr Lal PathLabs

Dr. Lal PathLabs Limited

CIN: L74899DL1995PLC065388
Regd. Office: Block E, Sector-18, Rohini, New Delhi- 110085
Corporate Office: 12th Floor, Tower B, SAS Tower, Medicity, Sector-38, Gurugram-122 001, Haryana
Phone: +91 124 3016500; **Fax:** +91 124 4234468; **Website:** www.lalpathlabs.com; **Email:** cs@lalpathlabs.com

Extract of Consolidated Financial Results for the quarter ended 30 June, 2020

(Rs. in million except as stated)

S. No.	Particulars	3 months ended 30 June, 2020	Year ended 31 March, 2020	Corresponding 3 months ended 30 June, 2019
		(Unaudited)	(Audited)	(Unaudited)
1	Total Income from Operations	2,774	13,854	3,496
2	Net Profit for the period before Tax and Exceptional items#	381	3,105	894
3	Net Profit for the period before Tax and after Exceptional items#	381	3,105	894
4	Net Profit for the period after Tax and after Exceptional items#	284	2,276	591
5	Total Comprehensive Income for the period after tax#	275	2,265	595
6	Paid up Equity Share Capital (face value of Rs. 10/- per share)	833	833	833
7	Earnings Per Share (of Rs. 10/- each) (not annualised)			
	(a) Basic (In Rs.)	3.45	27.42	7.14
	(b) Diluted (In Rs.)	3.44	27.37	7.13

#Before non-controlling Interest

Notes:

i. Key numbers of the Standalone Results are as under:

(Rs. in million except as stated)

S. No.	Particulars	3 months ended 30 June, 2020	Year ended 31 March, 2020	Corresponding 3 months ended 30 June, 2019
		(Unaudited)	(Audited)	(Unaudited)
1	Total Income from Operations	2,661	13,312	3,386
2	Profit for the period before Tax	385	3,027	867
3	Profit for the period after Tax	288	2,232	573
4	Total comprehensive income	279	2,221	577

ii. The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 31 July, 2020.

iii. The Board of Directors, which has been identified as being the chief operating decision maker (CODM), evaluates the Group's performance, allocates resources based on the analysis of the various performance indicators of the Group as a single unit. Therefore there is no reportable segment for the Group, in accordance with the requirements of Indian Accounting Standard 108- 'Operating Segments', prescribed under Section 133 of the Companies Act, 2013.

iv. The above is an extract of the detailed format of Quarterly financial results as per Ind AS filed with the Stock Exchange under Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015. The full Financial Results of the Quarter ended is available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and the Company's website (www.lalpathlabs.com).

For and on behalf of the Board of Directors of
Dr. Lal PathLabs Limited

Place: Gurugram
Date: 31 July, 2020

Dr. Om Prakash Manchanda
Managing Director